Drugs available in the Open Targets database that act on the biomarkers that associated with dementias and are hypothized to reduce the risk. In total 64 different drugs were identified. Drug_ID CHEMBL2107842 CHEMBL2107842 CHEMBL1743007 CHEMBL1743007 CHEMBL1743007 CHEMBL1201506 CHEMBL1201506 CHEMBL1201506 CHEMBL1201506 CHEMBL2109150 CHEMBL2109150 CHEMBL2109150 CHEMBL2109150 CHEMBL1201576 CHEMBL1201576 CHEMBL1201576 2 Completed CHEMBL1743007 Drug_name Type Mechanism_of_action Action_type Disease_ID Disease_name_originally_used_for Phase Status ALBINTERFERON ALFA-2B Protein Interferon alpha/beta receptor agonist Agonist EFO_0003047 hepatitis C virus infection 2 Completed ALBINTERFERON ALFA-2B Protein Interferon alpha/beta receptor agonist Agonist EFO_0004220 chronic hepatitis C virus infection DARATUMUMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Inhibitor EFO_0000330 childhood acute myeloid leukemia 1 Recruiting DARATUMUMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Inhibitor EFO_0000519 glioblastoma multiforme 1 Not yet recruiting DARATUMUMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Inhibitor EFO_0000673 prostate adenocarcinoma 1 Active, not recruiting DARATUMUMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Inhibitor EFO_0001378 multiple myeloma 1 Withdrawn GEMTUZUMAB OZOGAMICIN Antibody Myeloid cell surface antigen CD33 binding agent Binding agent EFO_0000565 leukemia 1 Terminated GEMTUZUMAB OZOGAMICIN Antibody Myeloid cell surface antigen CD33 binding agent Binding agent EFO_1000309 Juvenile Myelomonocytic Leukemia 1 Terminated GEMTUZUMAB OZOGAMICIN Antibody Myeloid cell surface antigen CD33 binding agent Binding agent MONDO_0019457 therapy related acute myeloid leukemia and myelodysplastic syndrome 1 Recruiting GEMTUZUMAB OZOGAMICIN Antibody Myeloid cell surface antigen CD33 binding agent Binding agent EFO_0000222 acute myeloid leukemia 0 Active, not recruiting LINTUZUMAB Antibody Myeloid cell surface antigen CD33 other Other EFO_0000222 acute myeloid leukemia 1 Not yet recruiting LINTUZUMAB Antibody Myeloid cell surface antigen CD33 other Other EFO_0000565 leukemia 1 Active, not recruiting LINTUZUMAB Antibody Myeloid cell surface antigen CD33 other Other EFO_0001378 multiple myeloma 1 Active, not recruiting LINTUZUMAB Antibody Myeloid cell surface antigen CD33 other Other EFO_1001779 chronic myelomonocytic leukemia 1 Completed RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0000772 pneumococcal infection 2 Active, not recruiting RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0002612 human herpesvirus 8 infection 2 Recruiting RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0002689 antiphospholipid syndrome 2 Completed RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0003032 anaplastic large cell lymphoma 2 Completed CHEMBL1743007 DARATUMUMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Inhibitor EFO_0003060 non-small cell lung carcinoma 1 Completed CHEMBL1743026 GEVOKIZUMAB Antibody Interleukin-1 beta negative allosteric modulator Negative allosteric modulator EFO_1001231 uveitis 3 Terminated CHEMBL4297236 LISOCABTAGENE MARALEUCEL Gene B-lymphocyte antigen CD19 binding agent Binding agent EFO_0005952 non-Hodgkins lymphoma 2 Recruiting CHEMBL1201576 RITUXIMAB Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0003100 peripheral neuropathy 2 Unknown status Source https://clinicaltrials.